"The voice for cancer physicians and their patients in Massachusetts."

FDA Approves durvalumab (Infinzi) for patients with unresectable state III NSCLC

27 Feb 2018 1:44 PM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approved durvalumab (Infinzi; AstraZeneca) for patients with unresectable stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. Read full press release

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software